Antibody Engineering Services
Receive your quote directly from the manufacturer.
Great partner for antibody engineering
Drug discovery
We have done three antibody engineering projects with Absolute Antibodies. Excellent and effective work. I highly recommend them.
Review Date: 28 Mar 2026 | Absolute Antibody
Absolute Antibody has developed a proprietary cloning system to enable rapid reformatting of antibodies into almost any format. Its antibody engineering services include chimerization, humanization, isotype switching and the manufacturing of recombinant antibody fragments and bispecific antibodies.
Bispecific ADCs targeting the cancer, not the patient
Tuesday, July 28 at 15:00 BST | 16:00 CEST | 10:00 EDT | 07:00 PDT
Bispecific antibody-drug conjugates (ADCs) represent an emerging frontier in targeted cancer therapy, combining the precision of antibody-based targeting with the potency of cytotoxic payloads. By recognizing two distinct tumor-associated markers rather than one, bispecific ADCs can improve tumor selectivity, helping to distinguish cancer cells from healthy tissue and potentially reducing off-target effects. As the field advances, researchers are exploring innovative approaches to address longstanding challenges in efficacy, safety, and patient outcomes, making bispecific ADCs a rapidly growing area of interest in oncology research and drug development.
This SelectScience webinar introduces BiVictriX Therapeutics and its role as an early pioneer in bispecific, logic gated, ADCs. It will cover how ADCs are reshaping targeted cancer therapy and why bispecific targeting offers a route to improved tumor selectivity and reduced off-tumor toxicity. The presentation will also explore the key steps to take when designing a bispecific ADC, including target selection, antibody format, linker strategy, and payload choice, and how these decisions influence efficacy, safety, and clinical potential.
Antibody expertise and bespoke reagents elevate life sciences research
See how Life Science Group and Absolute Antibody partner to deliver a flexible antibody offering for future-focused life sciences research
